dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
dasatinib g.l. 100 mg-filmtabletten
g.l. pharma gmbh - dasatinib -
dasatinib g.l. 140 mg-filmtabletten
g.l. pharma gmbh - dasatinib -
dasatinib g.l. 20 mg-filmtabletten
g.l. pharma gmbh - dasatinib -
dasatinib g.l. 50 mg-filmtabletten
g.l. pharma gmbh - dasatinib -
dasatinib g.l. 70 mg-filmtabletten
g.l. pharma gmbh - dasatinib -
dasatinib g.l. 80 mg-filmtabletten
g.l. pharma gmbh - dasatinib -
dasatinib g.l. pharma 100 mg-filmtabletten
g.l. pharma gmbh - dasatinib -
dasatinib g.l. pharma 140 mg-filmtabletten
g.l. pharma gmbh - dasatinib -